[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585088":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":11,"studyPopulation":11,"armGroups":53,"interventions":63,"overallOfficials":11,"centralContacts":72,"locations":78,"responsibleParty":95,"collaborators":11,"id":97,"slug":11,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":11,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":11,"overallStatus":115,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,16,19,21,23,25,28,30,32,34,36,38,41,43],{"measure":10,"description":11,"timeFrame":12},"The incidence of adverse events (AEs)",null,"A single-ascending dose (SAD) study ：up to 1week; multiple-ascending dose (MAD) study and food effect (FE) study : up to2weeks",{"measure":14,"description":11,"timeFrame":15},"Number of participants with abnormal lab values","SAD ：up to 1week; MAD and FE : up to2weeks",{"measure":17,"description":11,"timeFrame":18},"Single Ascending Dose Cohorts : Cmax","From Day1 to Day3",{"measure":20,"description":11,"timeFrame":18},"Single Ascending Dose Cohorts : AUC0-∞",{"measure":22,"description":11,"timeFrame":18},"Single Ascending Dose Cohorts : Tmax",{"measure":24,"description":11,"timeFrame":18},"Single Ascending Dose Cohorts : t½",{"measure":26,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: Cmax,ss","Day1 , Day10",{"measure":29,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: Cmin,ss",{"measure":31,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: Cavg,ss",{"measure":33,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: Tmax,ss",{"measure":35,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: AUC0-τ",{"measure":37,"description":11,"timeFrame":27},"Multiple Ascending Dose Cohorts: t½,",{"measure":39,"description":11,"timeFrame":40},"Food Effect Cohorts: Cmax","From Day1 to Day4 ， From Day8 to Day11",{"measure":42,"description":11,"timeFrame":40},"Food Effect Cohorts: Tmax",{"measure":44,"description":11,"timeFrame":40},"Food Effect Cohorts: AUC0-t",{"allocation":46,"interventionModel":47,"interventionModelDescription":11,"primaryPurpose":6,"observationalModel":11,"timePerspective":11,"maskingInfo":48},"RANDOMIZED","SEQUENTIAL",{"masking":49,"maskingDescription":11,"whoMasked":50},"DOUBLE",[51,52],"PARTICIPANT","INVESTIGATOR",[54,59],{"label":55,"type":56,"description":11,"interventionNames":57},"WD-910 Take a fixed dose of WD-910 tablets orally","EXPERIMENTAL",[58],"Drug: WD-910 tablet",{"label":60,"type":56,"description":11,"interventionNames":61},"WD-910 Tablets Placebo Take a fixed dose of WD-910 tablets Placebo orally",[62],"Drug: WD-910 Tablets Placebo",[64,69],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":11},"DRUG","WD-910 tablet","Administered P.O.",[55],{"type":65,"name":70,"description":67,"armGroupLabels":71,"otherNames":11},"WD-910 Tablets Placebo",[60],[73],{"name":74,"role":75,"phone":76,"phoneExt":11,"email":77},"Arockiaa Joseph","CONTACT","+61 459 661 281","c.trollip@nucleusnetwork.com.au",[79],{"facility":80,"status":11,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"Nucleus Network Pty Ltd","Melbourne","Victoria","3004","Australia","AU",{"type":87,"coordinates":88},"Point",[89,90],144.96332,-37.814,{"lat":90,"lon":89},[93],{"name":94,"role":75,"phone":76,"phoneExt":11,"email":77},"Joseph",{"type":96,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100585088",false,"NCT06897813","A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants","Inclusion Criteria:\n\n* Aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between 18 to 32 kg\u002Fm2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg\n\nExclusion Criteria:\n\n* Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.\n* Poor pill swallowing ability",true,"ALL","18 Years","55 Years",{"count":107,"type":108},68,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed",[114],"Healthy Participants","NOT_YET_RECRUITING","2025-03-26",{"date":118,"type":119},"2025-04-02","ACTUAL",{"date":121,"type":108},"2025-06-30",{"date":123,"type":108},"2025-12-31",{"name":5,"class":6},1]